REGENXBIO, Inc. (RGNX)
8.57
+0.49
(+6.06%)
USD |
NASDAQ |
Feb 25, 11:29
REGENXBIO Research and Development Expense (Quarterly) : 52.22M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 218.89M |
| Omeros Corp. | 15.76M |
| AbbVie, Inc. | 2.579B |
| CytomX Therapeutics, Inc. | 15.31M |
| Krystal Biotech, Inc. | 13.23M |